Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1009P - Current strategies of cell and gene therapy for solid tumors: Preliminary results of the joint international ESMO and EBMT Cell Therapy and Immunobiology Working Party questionnaire-based survey

Date

16 Sep 2021

Session

ePoster Display

Presenters

Patrizia Comoli

Citation

Annals of Oncology (2021) 32 (suppl_5): S829-S866. 10.1016/annonc/annonc705

Authors

P. Comoli1, G. Pentheroudakis2, P. Pedrazzoli3, A. Ruggeri4, U. Koehl5, F. Lordick6, K. Mauff7, J.D. Hoogenboom8, A. Urbano-Ispizua9, S. Peters10, C. Chabannon11, J.B.A.G. Haanen12

Author affiliations

  • 1 Cell Factory And Pediatric Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, 27100 - Pavia/IT
  • 2 Medical Oncology, University of Ioannina, 45110 - Ioannina/GR
  • 3 Oncology Department, Fondazione IRCCS Policlinico San Matteo, 27100 - Pavia/IT
  • 4 Pediatric Hematology And Bmt Unit, San Raffaele Scientific Institute, 0039 - Milan/IT
  • 5 Institute Of Cellular Therapeutics, Hannover Medical School, 30625 - Hannover/DE
  • 6 Medical Oncology, Universitätsklinikum Leipzig, 04103 - Leipzig/DE
  • 7 Statistical Unit, EBMT, 2333 - Leiden/NL
  • 8 Study Unit, EBMT, 2333 - Leiden/NL
  • 9 Hematology Department, Clinic University Hospital, 08036 - Barcellona/ES
  • 10 Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, 1011 - Lausanne/CH
  • 11 Departement De Biologie Du Cancer, Institut Paoli-Calmettes, 13273 - Marseille, Cedex/FR
  • 12 Medical Oncology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
More

Abstract 1009P

Background

Among novel strategies for treatment of solid tumors (ST), cell and/or gene therapy (CT/GT) products are increasingly under investigation, also based on encouraging results observed in lymphoid cancers with industry-manufactured CAR-T-cells. Available information on ongoing studies in ST is limited, due to the variety of programs and infrastructures involved in advanced therapy medicinal products (ATMPs) manufacturing and delivery.

Methods

This study aimed to describe the current landscape of CT/GT developments for treatment of ST from Jan 2018 to Dec 2020 by means of a web-based questionnaire circulated within the ESMO and EBMT centers.

Results

147 questionnaires were returned from 53 countries, 22% of the respondents were involved in CT/GT trials during the study period and 16% indicated their intention to start a CT/GT program. The majority of the active centers treated only adults (88%), while a minority exclusively or partially treated children (12%); 50% of the centers treated 1-5 pts, while a quarter enrolled more than 20 pts. Almost half of the studies were dedicated to melanoma or lung cancer; GI tract tumors, bone sarcomas, head & neck and gynecological cancers were also targeted. Evaluated ATMPs were mainly ex-vivo manipulated T lymphs, cultured and, in more than 50% of the cases, gene-modified either with CAR sequence or TCR transgene. TILs were the most frequently used non-gene modified products. In as many as 67% of the cases, ATMPs were combined with other treatment modalities, largely represented by ICIs. Small scale cell and gene engineering was mostly performed onsite by point-of-care manufacturing facilities. A minority of the studies were supported by EU funding.

Conclusions

Our survey shows that, although increasingly used, gene-modified T-cells represent little more than 50% of ATMPs employed in ST. Many clinical trials are based on point-of-care ATMPs production at academic centers, although industry-sponsored trials are running in at least half of the centers. In perspective, while waiting for breakthrough cellular products to treat ST, the field may benefit from network models for ATMPs production in academic centers.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

S. Peters: Consultation/Advisory role: AbbVie, Amgen, AstraZeneca, Bayer, Beigene, Biocartis, Bio Invent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, Elsevier, F. Hoffmann-La Roche/Genentech, Foundation Medicine, Illumina, Incyte, IQVIA, Janssen, Medscape, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Novartis, PharmaMar, Phosplatin Therapeutics, Pfizer, Regeneron, Sanofi, Seattle Genetics, Takeda, Vaccibody; Talk in a company’s organized public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, e-cancer, Eli Lilly, F. Hoffmann-La Roche/Genentech, Illumina, Medscape, Merck Sharp and Dohme, Novartis, PER, Pfizer, Prime, RTP, Sanofi, Takeda; Receipt of grants/research supports: (Sub)investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, AstraZeneca, Biodesix, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, F. Hoffmann-La Roche/Genentech, GSK, Illumina, Lilly, Merck Sharp and Dohme, Merck Serono, Mirati, Novartis, and Pfizer, Phosplatin Therapeutics.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.